Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 7/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 10/20 | 0.39 |
| ▸ | BIRC3 | Q13489 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067429 | 1.00 | TNF (0.44) | TNFCYP3A4XIAPBIRC2BIRC3 | |
| SCHEMBL22450861 | 0.94 | TNF (0.43) | TNFCYP3A4XIAPBIRC2BIRC3 | |
| SCHEMBL24067340 | 0.94 | TNF (0.43) | TNFCYP3A4XIAPBIRC2BIRC3 | |
| SCHEMBL22450858 | 0.93 | TNF (0.39) | TNFCYP3A4XIAPBIRC2BIRC3 | |
| SCHEMBL24488643 | 0.92 | TNF (0.41) | TNFCYP3A4XIAPBIRC2BIRC3 | |
| SCHEMBL22450620 | 0.92 | TNF (0.46) | TNFCYP3A4XIAPBIRC2BIRC3 | |
| SCHEMBL22450683 | 0.90 | TNF (0.43) | TNFCYP3A4XIAPBIRC2BIRC3 | |
| SCHEMBL24182144 | 0.89 | TNF (0.40) | TNFCYP3A4XIAPBIRC2BIRC3 | |
| SCHEMBL24182198 | 0.88 | TNF (0.53) | TNFCYP3A4XIAPBIRC2BIRC3 | |
| SCHEMBL22450736 | 0.88 | TNF (0.53) | TNFCYP3A4XIAPBIRC2BIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| EP-3936126-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | TNF 1106/4885CYP3A4 4540/4885XIAP 2/4885 |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | BIRC7, BIRC5, BIRC2 | TNF 1538/4885CYP3A4 4774/4885XIAP 6/4885 |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | BIRC7, BIRC5, BIRC2 | TNF 1538/4885CYP3A4 4774/4885XIAP 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.